The Autoinjector Market Size is valued at 1000.0 Million in 2023 and is predicted to reach 3085.4 Million by the year 2031 at a 15.1 % CAGR during the forecast period for 2023-2031.
Autoinjectors are pen-like devices that deliver a fixed dose of medication to a patient and are meant to be self-administered. Autoinjectors are gradually becoming the gold standard in the treatment of anaphylaxis, multiple sclerosis, and rheumatoid arthritis. The majority of autoinjectors are spring-loaded, and self-injection is a simple technique. These devices can assist patients in preventing needle stick injuries and lessen needle fear. To improve the simplicity of use and alleviate the anxiety associated with self-administration of intramuscular injections, autoinjector manufacturers are focused on user-centric approaches. The autoinjector market is expected to grow significantly, given the rise in anaphylactic cases. Furthermore, firms' increased R&D efforts to create simple, cost-effective, and innovative technology-based autoinjectors for the treatment of chronic diseases such as rheumatoid arthritis and multiple sclerosis are likely to fuel market growth throughout the forecast period.
On the other hand, there are a variety of chronic conditions that necessitate daily injections. The illness's diversity, on the other hand, requires a combination of autoinjector requirements. The injection capacity, dosage, length, and thickness must be varied for each medication. Different types of autoinjectors result from these factors. The absence of appropriate autoinjectors and product variety may have a negative impact on the autoinjector business. The OEM is untrained in the production of several medications. The major players are addressing these market problems. The market is attempting to meet this problem by conducting additional research.
Market Segmentation:
The Global Autoinjectors Market is segmented on the basis of Type of Autoinjector, Route of Administration, Type of Molecule, Therapeutic Indication. Type of Autoinjector segment includes Disposable and Reusable, Route of Administration segment includes Subcutaneous and Intramuscular, Type of Molecule segment includes Monoclonal Antibody, Peptide, Protein, and Small Molecule, Therapeutic Indication segment includes Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Migraine, Diabetes)
Based on Therapeutic Indication, rheumatoid arthritis is accounted as a significant contributor to the Global Autoinjectors Market.
In 2021, the market for autoinjectors was dominated by rheumatoid arthritis (RA). The high prevalence of this group accounts for its significant share, and the rising prevalence of RA is driving up demand for autoinjectors in this treatment area. Arthritis, RA, gout, lupus, and fibromyalgia affect an estimated 20% of the total population in the United States each year.
In The Region, The North America Global Autoinjectors Market Holds A Significant Revenue Share.
The Asia Pacific market is expected to outperform other regional players during the projected period. In this area, autoinjectors are in high demand. The rising number of diabetics is driving up demand for the product. Furthermore, the healthcare infrastructure is growing at a breakneck speed, and it leads to an increase in the production of autoinjectors. In this region, home care and self-administration of chronic conditions rise. Many patients and their families learn to use autoinjectors for non-urgent situations. The existence of leading autoinjector firms is beneficial to market growth. In the Asia-Pacific area, autoinjectors are constantly evolving and in high demand. Furthermore, an increase in the occurrences of anaphylaxis, rheumatoid arthritis, and other disorders such as anaemia and migraine and future technological developments by firms are likely to propel the market forward.
To keep and grow their customer base, key players are focusing on portable and user-friendly auto-injectors. To protect their brand equity, companies like Mylan N.V. and Eli Lilly and Company are focusing more on user-friendly auto-injectors. New entrants are concentrating their efforts on reaching emerging markets by introducing low-cost auto-injector devices. Some businesses, such as Mylan N.V., Teva Pharmaceuticals, and others, are launching generic versions of cost-effective auto-injectors devices and targeting emerging markets, such as Asia-Pacific, the Middle East, and others, in order to stay competitive and grow in the global Auto-Injectors Market.
Competitive Landscape
Some of The Key Players in The Autoinjector Market:
-
Antares Pharma, Inc.
-
Becton, Dickinson and Company (BD)
-
Bespak
-
DALI Medical Device
-
Elcam Medical
-
Haselmeier GmbH
-
Jiangsu Delfu medical device
-
Kaleo, Inc.
-
Oval Medical Technologies Ltd.
-
Owen Mumford Ltd.
-
Philip-Medisize, LLC
-
Recipharm AB
-
SHL Medical
-
Solteam Incorporation Co., Ltd.
-
Union Medico
-
West Pharmaceutical Services, Inc.
-
Ypsomed Holding AG.
-
AktiVax
-
Amneal Pharmaceuticals
-
Nemera
-
Nuance Designs
-
Windgap Medical
-
Xeris Pharmaceuticals
-
Zion Clinical Pharmacy
The Autoinjector Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 1090.0 Million |
|
Revenue Forecast In 2031 |
USD 3085.4 Million |
|
Growth Rate CAGR |
CAGR of 15.1 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million, Volume (Unit), and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Autoinjector, Route of Administration, Type of Molecule, Therapeutic Indication |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Amgen Inc., Antares Pharma, Becton, Dickinson, And Company (BD), ELI LILLY AND COMPANY, Johnson & Johnson, MYLAN N.V., Novartis AG, SHL MEDICAL AG, TEVA Pharmaceutical Industries LTD., YPSOMED AG, ATS Automation Tooling Systems Inc. Owen Mumford Ltd., SHL Group, Oval Medical Technologies Ltd., E3D Elcam Drug Delivery Devices, kaleo, Inc., Crossject, Gerresheimer AG. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
